Indaptus Therapeutics, Inc. (INDP)
Indaptus Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in New York City, NY, US. The stock last traded at $1.08, down 9.24% on the session, giving a market capitalisation of $122.3M. On trailing twelve-month figures it carries a trailing P/E of -0.17, a net margin of 0.0%. Its beta of 1.18 implies it has historically moved more than the broad market.
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
Indaptus Therapeutics, Inc. is most often compared with the following Healthcare names: